Phillip Brunson, OD
Optometrist · Houston, TXNPI 1265435507
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $154,990 of the $214,202 with a category attached, or 72.4%. 32 manufacturers reported payments, led by Tarsus Pharmaceuticals, Inc. at 41.8% of the total. 2025 is the largest year on record at $69,446, 2.4 times the $28,468 reported in 2019. Among optometrist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 757 payments — averaging $282.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$90K
- AbbVie$83K
- Novartis$14K
- Alcon$7K
- Sun Pharmaceutical Industries Inc.$6K
- Eyevance Pharmaceuticals LLC$5K
- plus $11K from 26 others
Across 23 payments — averaging $23,986 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$458K
- Johnson & Johnson Surgical Vision, Inc.$94K
What the payments were for
- Consulting fees$15,9587%
- Speaking & faculty fees$154,99072%
- Travel & lodging$21,77810%
- Food & beverage$21,44110%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 121 | $89,546 |
| AbbVie(2 entities) | 313 | $83,318 |
| Novartis | 58 | $13,766 |
| Alcon | 78 | $6,514 |
| Sun Pharmaceutical Industries Inc. | 45 | $5,652 |
| Eyevance Pharmaceuticals LLC | 13 | $4,532 |
| Alcon Research LLC | 1 | $3,750 |
| Shire North American Group Inc | 6 | $2,930 |
| Oyster Point Pharma, Inc. | 24 | $936 |
| Carl Zeiss Meditec USA, Inc. | 4 | $388 |
| Bausch & Lomb Americas Inc. | 20 | $380 |
| Biotissue Holdings Inc. | 14 | $367 |
| Dompe US, Inc. | 8 | $271 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $265 |
| Glaukos Corporation | 3 | $233 |
| Amgen | 4 | $212 |
| Johnson & Johnson Vision Care, Inc. | 6 | $182 |
| Harrow Eye, LLC | 6 | $169 |
| NEW World Medical,inc. | 1 | $165 |
| Kala Pharmaceuticals, Inc. | 8 | $141 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $114 |
| Astellas Pharma US Inc | 2 | $58 |
| Sight Sciences, Inc. | 3 | $58 |
| Carl Zeiss Meditec, Inc. | 1 | $56 |
| Rayner Intraocular Lenses Limited | 1 | $45 |
| Maculogix, Inc. | 1 | $33 |
| Coopervision Inc. | 1 | $26 |
| Aerie Pharmaceuticals, Inc. | 1 | $23 |
| Mallinckrodt Enterprises LLC | 1 | $22 |
| Topcon Healthcare Solutions, Inc. | 1 | $21 |
| Derma Sciences, Inc. | 1 | $17 |
| Quidel Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XDEMVY$80,028
- VUITY$49,444
- XIIDRA$15,133
- RESTASIS$14,194
- RESTASIS MULTIDOSE$11,530
- WaveLight EX500 Excimer Laser$4,898
- CEQUA$4,653
- Wavelight$4,043
- Flarex$3,392
- Wavelight Refractive Suite$2,347
- LUMIGAN$2,270
- Tobradex ST$1,000
- TYRVAYA$525
- COMBIGAN$400
- DURYSTA$351
- Hydrus Microstent$246
- Kahook Dual Blade$165
- Clearpath$165
- Ahmed Glaucoma Valve$165
- Streamline$165
How this compares
$214,202 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 147 | $129,406 |
| Cyclosporine | 96 | $57,893 |
| XiidraLifitegrast | 44 | $53,070 |
| LumiganBimatoprost | 90 | $43,434 |
| MieboPerfluorohexyloctane/Pf | 20 | $18,924 |
| CequaCyclosporine | 12 | $14,828 |
| CombiganBrimonidine Tartrate/Timolol | 27 | $12,717 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 72 | $11,045 |
| Loteprednol Etabonate | 27 | $3,269 |
| Latanoprost | 189 | $2,591 |
| Brimonidine Tartrate | 47 | $2,349 |
| Prednisolone Acetate | 56 | $1,612 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 27 | $980 |
| Timolol Maleate | 53 | $836 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 28 | $782 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $83,318 | $185,558264 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $380 | $71,99464 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $5,652 | $14,82812 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $114 | $3,26927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.
Other optometrist in Houston
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$547K
- Bridgitte LeeHouston$222K
- Maria WalkerHouston$128K
- Seema NandaHouston$87K
- Danica MarrelliHouston$87K
- Richard BakerHouston$78K
- Karen LeeHouston$71K
- Nishi MehdirattaHouston$45K
- Ali MostaghimiHouston$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.